NasoNeb Nasal Nebulizer

Choosing the right intranasal drug delivery system matters.

The NasoNeb® Nasal Nebulizer delivers a deep, penetrating aerosol to the nasal and paranasal sinus cavities with virtually no incidental pulmonary delivery of drugs and the risk of resultant complications common with small particle nebulizers. 4,8,9,11

NasoNeb-delivered Budesonide, (Pulmicort Respules® 0.25 mg/2ml), demonstrated statistically-significant objective and subjective outcomes in a peer-reviewed clinical study. 8,9

NasoNeb-delivered Budesonide (Pulmicort Respules®, 0.25 mg/2ml) demonstrated a statistically-significant 50 LPM increase in daily nasal peak inspiratory flow (NPIF) from baseline to endpoint in the treatment arm of a parallel, randomized, double-blinded, placebo controlled clinical trial in a perennial allergic rhinitis patient population.

The authors concluded, in part: " it stands to reason that administering intranasal corticosteroids, which have been shown effective time and again as a treatment for perennial allergic rhinitis, would prove to be even more effective when delivered in this novel way." Daily nasal peak inspiratory flow on treatment. Median values are depicted. The x-axis shows the study timeline with B = baseline measurement. *p < 0.005 vs baseline for the group on budesonide


Patients also reported statistically-significant improvements in total nasal symptoms scores (TNSS) and rhinoconjunctivitis quality of life scores.

Daily TNSS on treatment. Median values are depicted. The x-axis shows the study timeline with B = baseline measurement. *p < 0.05 vs respective baselines within treatment groups.


The broad deposition, high intranasal drug retention and no pulmonary deposition of the NasoNeb Nebulizer makes it the best choice for intranasal drug delivery, as demonstrated by positive outcomes data. 4,8,9,11

NasoNeb delivers up to 71 times more medication

Other technologies deliver only 3-10% of the drug to the nasal and paranasal sinus cavities. 5,8,9

  • The patented NasoNeb® Nasal Nebulizer has been clinically-shown to deposit a low volume, high concentration of medication to the nasal and paranasal sinus cavities.

    • Studies, including a peer-reviewed journal article, demonstrate that the NasoNeb System deposits medication to the nasal and paranasal sinus cavities, including the frontal recess/sinus, spheno-ethmoid recess, ethmoid cavity, sphenoid and maxillary sinuses, all turbinates, the middle meatus and olfactory cleft. 4,11
  • This deposition pattern matters. In a study of NasoNeb-delivered pharmaceutical therapy, the investigators reported a statistically-significant increase in Nasal Peak Inspiratory Flow of approximately 50 LPM (p<0.005) within the treatment arm from baseline to endpoint during a 26 day follow up period. 8,9

  • The FDA guidance document on nasal drug delivery states "Particles or droplets that are aerodynamically smaller than the standard 5 micron upper bound of the respirable fragment size can be inhaled. For nasal deposition, the optimal droplet or particle size should be, on the whole, substantially larger than the respirable fragment size". 19

Table 1. Percentage of NasoNeb-generated particles by size, in microns

  • The NasoNeb Nasal Nebulizer is the only large particle, low volume, high concentration delivery system available that is backed by clinical data. 4,8,9,11

    • Small particle nebulizers, often adapted pulmonary nebulizers, deliver a substantial fraction of the drug to the pulmonary system.

      • This can increase systemic bioavailability of the drug, leading to systemic side effects. 20

      • Additional unwanted side effects may include alteration of voice 16, antimicrobial resistance 15, eosinophilic pneumonia 16, chronic cough 16, and reduced lung function. 11

      • Studies have shown that only 3% of the drug reaches the intended nasal and paranasal sinus cavities when delivered by these devices. 8,9
    • Aerosol-generating powered nasal irrigators are sometimes prescribed off-label.

      • These devices are designed for saline irrigation and feature vents that capture spent fluid that is directed into a waste container for disposal by the user. 21,22

      • These vents enable airflow from the stream to be vented to the environment and directed away from the nose, reducing their ability to deposit fluid deep into the nasal and paranasal sinus cavities. 21,22
  • The NasoNeb System delivers large particles that are readily filtered by the nose to ensure a large percentage of medication is delivered where the physician intended and that no drug is delivered to the lungs, reducing the risk of unwanted complications. 4,11

    • These particles are delivered via a positive pressure airstream that ensures the medication reaches all of the nasal and paranasal sinus cavities. 4,11
  • The NasoNeb System delivers a low volume of liquid to ensure that the medication stays in the nasal cavity.

    • Unlike medicated irrigation solutions of which 97.2 - 98.6% or more run down the sink 4,8, the NasoNeb has the capacity to deliver between 0.2 - 15 ml of solution that is retained in the nasal and paranasal sinus cavities. 4,11,22
  • Many liquid medications require refrigeration to extend shelf life. Repeated exposure to cold fluid irrigation has been shown to cause a unique complication of exostoses of the paranasal sinus cavities in post-surgical patients. 1,6,14,15

    • Exostoses are bony formations under the mucosa and are commonly seen in the ear canals of cold-water swimmers and surfers.

    • The time to warm irrigation solution to near room temperature requires 120 minute wait period from the time the medication is removed from the refrigerator. 7

    • This waiting period may reduce patient compliance and increase the likelihood of repeat cold fluid exposure should the patient not wait to perform the irrigation. 7

    • In this instance, the use of medicated irrigations could violate the "do no harm" oath. 7

    • The aerosolizing action of the NasoNeb System warms refrigerated solutions to near room temperature immediately, which may help to avoid the iatrogenic complication of exostoses from cold fluid irrigation. 7

Table 2. Comparing Intranasal Drug Delivery Systems

  • People who may benefit from pharmaceutical therapy delivered by the NasoNeb Nasal Nebulizer include but are not limited to the following:

    • Patients with recurrent nasal polyps

    • Post-sinus surgery patients with chronic nasal crusting and infection

    • Patients with smell disorders

    • Patients with infections who have had or are not candidates for sinus surgery

    • Patients suffering from recalcitrant allergic rhinitis

    • Patients suffering from other rhinologic conditions

The Optimal Intranasal Drug Delivery Solution

The NasoNeb Nasal Nebulizer is available by prescription only.
Where to purchase